Dr. Stanley Liauw serves as the Director of Clinical Operations and is the clinical lead for the genitourinary (GU) cancer program and the gastrointestinal (GI) cancer program within the Department of Radiation and Cellular Oncology at the University of Chicago. In the past 10 years on faculty, Dr. Liauw has developed research programs in these disease sites, with an interest in outcomes research and clinical trials. The central mission of his research is to conduct clinical studies to define current clinical outcomes and areas of need, develop hypotheses, and test novel regimens to reduce the morbidity or mortality of radiation therapy in the treatment of cancer.
A major focus of Dr. Liauw's efforts include the periodic analysis and reporting of cancer outcomes with radiation therapy. This work, derived from multiple institutional databases of more than 2000 patients, has resulted in numerous abstract presentations and publications in peer-reviewed journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology, Biology, Physics and Cancer. These contributions generally fall into 3 categories of interest: presenting hypotheses to improve the therapeutic ratio of therapy, studying the use of imaging in radiation oncology, and exploring potential markers of response to therapy.
A number of clinical protocols have been opened for patients with genitourinary and gastrointestinal cancers. Dr. Liauw has investigated and initiated trials for a: phase I study of dose escalated stereotactic body RT trial for unresectable pancreatic cancer, phase II quality of life study of oral hormonal therapy with RT for prostate cancer, phase I study for oligometastatic renal cell cancer, and phase I randomized study for hepatocellular carcinoma treated with RT and immunotherapy.
Outside of his research interests, Dr. Liauw has overseen several intradepartmental projects aimed at improving clinical workflow and patient safety, with potential downstream effects on patient and employee satisfaction. He served as the clinical lead for the implementation of intraoperative radiation therapy in 2015, as an Associate Editor for GI cancers for the International Journal of Radiation Oncology, Biology, and Physics, as an examiner and question writer for the American Board of Radiology for GU cancers, and an invited speaker for national and international educational lectures such as through the American Society of Radiation Oncology (ASTRO) and the American Urological Association. He has been an invited Visiting Professor for resident education at multiple institutions, and has been regularly recognized from the University of Chicago training program as a top educator. He has been an ad hoc reviewer of manuscripts for more than 20 scientific journals, including Journal of Clinical Oncology and the New England Journal of Medicine.
University of Florida
Gainesville, FL
Residency - Radiation Oncology
2006
Brigham and Women's Hospital
Boston, MA
Internship - Internal Medicine
2002
UT Southwestern Medical School
Dallas, TX
MD - Medicine
2001
MIT
Cambridge, MA
BS - Chemical Engineering
1997
Online correction of intrafraction motion during volumetric modulated arc therapy for prostate radiotherapy using fiducial-based kV imaging: A cohort study quantifying the frequency of shifts and analysis of men at highest risk.
Online correction of intrafraction motion during volumetric modulated arc therapy for prostate radiotherapy using fiducial-based kV imaging: A cohort study quantifying the frequency of shifts and analysis of men at highest risk. J Appl Clin Med Phys. 2025 Apr; 26(4):e14603.
PMID: 39824507
Evaluating Tumor Tissue Modified Viral (TTMV)-HPV DNA for the Early Detection of Anal Squamous Cell Carcinoma Recurrence.
Evaluating Tumor Tissue Modified Viral (TTMV)-HPV DNA for the Early Detection of Anal Squamous Cell Carcinoma Recurrence. Cancers (Basel). 2025 Jan 08; 17(2).
PMID: 39857955
Patterns of Recurrence Following Radiation and ADT for Pathologic Lymph Node-Positive Prostate Cancer: A Multi-institutional Study.
Patterns of Recurrence Following Radiation and ADT for Pathologic Lymph Node-Positive Prostate Cancer: A Multi-institutional Study. Pract Radiat Oncol. 2024 Dec 27.
PMID: 39733964
Genomic Classifiers To Guide Postprostatectomy Radiation Therapy: An Opening Movement in G-MINOR.
Genomic Classifiers To Guide Postprostatectomy Radiation Therapy: An Opening Movement in G-MINOR. Eur Urol. 2025 Feb; 87(2):238-239.
PMID: 39616001
Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma.
Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma. Clin Transl Radiat Oncol. 2024 Nov; 49:100879.
PMID: 39529961
Point/Counterpoint #2: Current Clinical Considerations With Nonoperative Management of Rectal Cancer.
Point/Counterpoint #2: Current Clinical Considerations With Nonoperative Management of Rectal Cancer. Cancer J. 2024 Jul-Aug 01; 30(4):256-263.
PMID: 39042777
Hormonal Therapy and Radiation Therapy in Prostate Cancer: 5-Year Outcomes From a Trial Evaluating Combined Androgen Blockade With 5-Alpha Reductase Inhibitors as an Alternative to Gonadotropin Releasing Hormone Agonists.
Hormonal Therapy and Radiation Therapy in Prostate Cancer: 5-Year Outcomes From a Trial Evaluating Combined Androgen Blockade With 5-Alpha Reductase Inhibitors as an Alternative to Gonadotropin Releasing Hormone Agonists. Clin Genitourin Cancer. 2024 Aug; 22(4):102103.
PMID: 38781786
Bladder-Preserving Trimodality Therapy With Capecitabine.
Bladder-Preserving Trimodality Therapy With Capecitabine. Clin Genitourin Cancer. 2024 04; 22(2):476-482.e1.
PMID: 38228414
Multidisciplinary Collaboration is Key.
Multidisciplinary Collaboration is Key. Int J Radiat Oncol Biol Phys. 2023 Dec 01; 117(5):1047-1048.
PMID: 37980133
Monitoring Intrafraction Motion of the Prostate During Radiation Therapy: Suggested Practice Points From a Focused Review.
Monitoring Intrafraction Motion of the Prostate During Radiation Therapy: Suggested Practice Points From a Focused Review. Pract Radiat Oncol. 2024 Mar-Apr; 14(2):146-153.
PMID: 37875222